The antitumor immunity of Lenti-HA was assessed in ectopic, orthotopic, and autochthonous HCC models, demonstrating that HMGN1 increased the antitumor immunity of AFP-expressing lentiviral vaccines in HCC mice and human cells, and thus providing a new therapeutic strategy for HCC [139]. Here, HMGN1 is linked to hepatocellular carcinoma.